Some public health experts, including Ashish Jha, former White House COVID coordinator, have expressed concern that vaccine hesitancy sentiment may depress flu vaccination rates during this critical Fall period. There have always been hurdles to flu vaccine adoption, and it’s fair to assume those hurdles might be raised a notch by COVID fatigue and added noise around the heavily promoted new RSV vaccine from Pfizer. As it turns out, however, NAXION’s recent self-funded survey of vaccine sentiment and intentions among consumers actively engaged with the healthcare system gives reason for optimism. Over the next year, we will be monitoring consumer sentiment and vaccination behavior outcomes with the goal of understanding the underlying motivational dynamics and improving predictive models. #COVID #flu #vaccine #marketingresearch #NAXION
CEO at NAXION
1yThis fall's vaccine trifecta is a really opportune moment to be examining the public appetite for respiratory vaccines while also enhancing our forecast models with updated calibrations. Rooting for brisk uptake on all three.